Full name
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)
NCT Number
NCT05334368
Geography
US
Non-US
Locations
Argentina, Australia, Belgium, Brazil, China, Czechia, Denmark, Germany, Greece, Hong Kong, Israel, Italy, Japan, Republic of Korea, Mexico, Poland, Romania, Spain, Turkey, United Kingdom, United States
Primary Endpoints
Frequency of HES flares. Up to 52 weeks
External Link
https://clinicaltrials.gov/study/NCT05334368
Order
2
Disease
Version
Phase
3
Status
Recruiting